# Engineering and targeting the sperm-specific calcium channel CatSper for contraception

> **NIH NIH R61** · YALE UNIVERSITY · 2024 · $425,827

## Abstract

PROJECT SUMMARY
 The high rate of unplanned pregnancies suggests that currently available contraceptive methods are not
effectively meeting the needs of women. In addition, contraceptive options for men are limited to vasectomy and
condoms, leaving a significant unmet need for contraception. Our long-term goal is to develop a non-steroidal,
effective contraceptive that provides a more comprehensive approach to birth control. We propose that the
sperm-specific CatSper calcium (Ca2+) channel is an ideal target for the development of such a new class of
contraceptives that has no negative side effects in either men or women, as the CatSper channel is a validated
target required for sperm capacitation and male fertility in both mice and humans. Drug inhibition of CatSper at
the post-testicular and pre-fertilization stages would work without off-target side effects due to its post-meiotic
expression in male germ cells and functional divergence from other calcium channels. The recently solved struc-
tures of CatSper highlight its high accessibility in the cell membrane, allowing the study of the mechanism of
action and reversible contraceptives. However, the inability to reconstitute the channel in vitro has been a bot-
tleneck in the development of drugs that directly target the CatSper channel.
 We have recently overcome this hurdle by creating chimeric CatSper channels that heterologously express
functional channels. Using this new tool, the overall goal here is to ultimately develop CatSper modulators that
inhibit human sperm function. To this end, in R61 phase, we will perform in-depth biophysical and functional
characterization of these novel chimeric channels and do molecular dynamics studies to gain new insights (Aim
1) and develop the necessary assays for primary and secondary screening that measure CatSper activity in
high-throughput modes (Aim 2). In the R33 phase, we will perform high-throughput screening for CatSper inhib-
itors as well as virtual screening (Aim 3), profile the identified hits, establish preliminary structure-activity rela-
tionships and perform the secondary screening (Aim 4), and test the selected compounds on human sperm
function (Aim 5). In the immediate term, successful completion of these aims will provide small molecule hits for
human CatSper that can be used for iterative lead generation. In the long term, the leads and knowledge gener-
ated will ultimately lead to the development of an innovative class of contraceptives targeting CatSper and sperm
capacitation with a mechanisms of action foundation.

## Key facts

- **NIH application ID:** 10823834
- **Project number:** 1R61HD114344-01
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Jean-Ju Lucia Chung
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $425,827
- **Award type:** 1
- **Project period:** 2024-02-01 → 2026-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10823834

## Citation

> US National Institutes of Health, RePORTER application 10823834, Engineering and targeting the sperm-specific calcium channel CatSper for contraception (1R61HD114344-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10823834. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*